Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.
What This Page Explains
Cardiovascular disease remains the leading cause of death globally, and aging is the primary risk factor. Fisetin's senolytic, anti-inflammatory, and antioxidant properties are all theoretically relevant to heart and vascular health. This page reviews the evidence on fisetin and cardiovascular health, including preclinical cardioprotection studies, the ongoing human vascular function trial (NCT06133634), and the absence of clinical cardiovascular outcome data. No one should use fisetin as a substitute for evidence-based cardiovascular care.
Heart Health Starts in Your Cells — Not Just Your Cholesterol
Cardiovascular disease is the leading killer, and aging is the root cause. Support your cells and your heart follows.
Detailed Evidence
CARDIOVASCULAR AGING AND SENESCENCE Vascular aging involves endothelial dysfunction, arterial stiffening, and atherosclerosis — all processes in which senescent cells accumulate and contribute via SASP-driven inflammation. Senescent endothelial cells, vascular smooth muscle cells, and macrophages have been identified in atherosclerotic plaques. The senolytic hypothesis is directly relevant to cardiovascular aging. PRECLINICAL CARDIOPROTECTION STUDIES In rodent and cell culture models, fisetin has shown cardioprotective effects: in ischemia-reperfusion injury models (heart attack simulation), fisetin reduced infarct size and preserved cardiac function; in cultured cardiomyocytes, fisetin reduced oxidative stress-induced cell death; in endothelial cell culture, fisetin improved nitric oxide bioavailability (key for vascular function); and fisetin reduced vascular inflammation markers. ATHEROSCLEROSIS MODELS In ApoE knockout mice (a model of atherosclerosis), fisetin administration reduced atherosclerotic plaque formation, decreased plaque inflammation, and improved plaque stability markers. These findings suggest potential anti-atherogenic activity, though this is preclinical only. THE NCT06133634 VASCULAR FUNCTION TRIAL The most relevant human study is the ongoing vascular function trial (NCT06133634) in older adults. This trial measures: arterial stiffness (pulse wave velocity); endothelial function (flow-mediated dilation); and vascular biomarkers. Results (expected 2026-2027) may provide the first human data on fisetin's vascular effects. However, this trial measures surrogate markers, not clinical cardiovascular outcomes (heart attack, stroke, mortality). COMPARISON TO ESTABLISHED CARDIOVASCULAR CARE Evidence-based cardiovascular care has far stronger support than any supplement: blood pressure management (lifestyle + medications); cholesterol management (statins, ezetimibe, PCSK9 inhibitors); antiplatelet therapy (aspirin in selected patients); diabetes and weight management; smoking cessation; Mediterranean diet; and regular exercise. Fisetin has preclinical evidence only and should never replace any of these. HUMAN EVIDENCE: SURROGATE MARKERS ONLY As of 2026, no published human trial has measured clinical cardiovascular outcomes (MACE — major adverse cardiovascular events) with fisetin. The vascular function trial may provide surrogate marker data, but surrogate markers (arterial stiffness, FMD) do not guarantee clinical benefit — many interventions improving surrogate markers fail to reduce actual cardiovascular events. SAFETY CONSIDERATIONS FOR CARDIAC PATIENTS Fisetin's potential CYP3A4/CYP1A2 interactions could affect the metabolism of cardiovascular medications (statins, anticoagulants, antiplatelet drugs). Cardiac patients should never take fisetin without cardiologist supervision. Anyone with cardiovascular disease should follow their cardiologist's treatment plan.
Evidence Hierarchy
Systematic Reviews & Meta-Analyses
Multiple high-quality trials combined
Randomized Controlled Trials (RCTs)
Gold standard for treatment efficacy
Observational Studies
Can show associations, not causation
Case Reports & Expert Opinion
Hypothesis-generating only
Preclinical (Lab/Animal) Studies
Should NOT be extrapolated to humans
The Reason 90% of Anti-Aging Supplements Don't Work
They target symptoms, not the root cause: cellular energy decline. ReCellence targets the mitochondria directly.
Study Quality Indicators
Higher Quality Indicators
- Large sample size (hundreds to thousands)
- Randomized and blinded design
- Placebo-controlled comparison
- Published in peer-reviewed journals
- Replicated in multiple studies
- Registered trial protocol before starting
Lower Quality Indicators
- Small sample size (under 100)
- No control group or blinding
- Manufacturer-funded with conflicts
- Only animal/cell studies
- Never replicated
- Published in predatory journals
Important Limitations
- • Supplement research often has methodological limitations
- • Results from one study may not generalize to all people
- • Marketing claims often exceed what research supports
- • Absence of evidence is not evidence of absence
- • Individual response to supplements varies widely
Quick Answers
Can fisetin prevent heart disease?
No human evidence supports fisetin for preventing heart disease. Preclinical models show cardioprotective effects, but no clinical cardiovascular outcome trial has been published. Evidence-based prevention includes diet, exercise, and risk factor management.
Does fisetin improve blood vessel function?
In endothelial cell culture, fisetin improved nitric oxide bioavailability. The ongoing NCT06133634 trial measures vascular function in humans — results expected 2026-2027. No published human data exists yet.
Can fisetin treat atherosclerosis?
In ApoE knockout mice, fisetin reduced plaque formation and improved stability. No human trial has tested fisetin for atherosclerosis. Atherosclerosis requires cardiologist-supervised care.
What is the NCT06133634 trial?
It's an ongoing human trial testing fisetin's effects on vascular function (arterial stiffness, endothelial function) in older adults. Results expected 2026-2027 may provide the first human vascular data — but surrogate markers, not clinical outcomes.
Does fisetin reduce heart attack risk?
No. No human trial has measured heart attack, stroke, or mortality (MACE) with fisetin. Surrogate markers like arterial stiffness do not guarantee clinical benefit. Statins and blood pressure management have proven outcome data.
Can fisetin replace statins?
Absolutely not. Statins have decades of clinical evidence proving reduced cardiovascular events and mortality. Fisetin has preclinical evidence only. Never substitute fisetin for prescribed cardiovascular medication.
How does fisetin affect endothelial cells?
In culture, fisetin improved nitric oxide bioavailability (key for vascular function) and reduced endothelial inflammation. Whether this occurs in humans at supplement doses is unproven.
Does fisetin protect against ischemia-reperfusion injury?
In rodent heart attack models, fisetin reduced infarct size and preserved cardiac function. This is preclinical only — acute cardiac events require emergency medical treatment.
Should cardiac patients take fisetin?
Cardiac patients should never take fisetin without cardiologist supervision. Potential CYP drug interactions could affect statins, anticoagulants, and antiplatelet drugs. Always inform your cardiologist about all supplements.
What is arterial stiffness?
Arterial stiffening is a hallmark of vascular aging, measured by pulse wave velocity. The NCT06133634 trial measures this. Stiffness correlates with cardiovascular risk but is a surrogate marker, not a clinical outcome.
Can fisetin lower blood pressure?
No human evidence supports fisetin for blood pressure. Blood pressure management has strong evidence for lifestyle (diet, exercise, salt reduction) and medications. Fisetin should not replace evidence-based hypertension treatment.
What is flow-mediated dilation (FMD)?
FMD measures endothelial function — how well arteries dilate in response to blood flow. The NCT06133634 trial measures FMD. Improved FMD is associated with cardiovascular health but is a surrogate marker.
Does fisetin reduce vascular inflammation?
In preclinical models, fisetin reduces vascular inflammation markers. Vascular inflammation contributes to atherosclerosis. Whether this occurs in humans is unproven.
Is fisetin better than Mediterranean diet for heart health?
No. The Mediterranean diet has strong clinical evidence for cardiovascular risk reduction (PREDIMED trial). Fisetin has preclinical evidence only. Diet and lifestyle are far better supported than any supplement.
What is the best approach to heart health?
Blood pressure and cholesterol management, diabetes and weight control, smoking cessation, Mediterranean diet, regular exercise, and cardiologist-supervised medication when needed. Fisetin should not replace any of these.
Key Research Facts
In ischemia-reperfusion (heart attack) rodent models, fisetin reduced infarct size and preserved cardiac function.
Moderate EvidenceCardioprotection studies — Multiple publications
In endothelial cell culture, fisetin improved nitric oxide bioavailability, key for vascular function.
Moderate EvidenceEndothelial function studies — Multiple publications
In ApoE knockout atherosclerosis mice, fisetin reduced plaque formation, decreased inflammation, and improved stability markers.
Moderate EvidenceAtherosclerosis model studies — Multiple publications
The NCT06133634 vascular function trial may provide the first human fisetin vascular data (2026-2027), but measures surrogate markers, not clinical outcomes.
Emerging EvidenceClinicalTrials.gov — NCT06133634
No published human trial has measured clinical cardiovascular outcomes (MACE — heart attack, stroke, mortality) with fisetin as of 2026.
Strong EvidenceClinicalTrials.gov / PubMed — registry + literature search
Statins have decades of clinical evidence proving reduced cardiovascular events and mortality — fisetin has no valid comparison.
Strong EvidenceCardiology clinical guidelines — ACC/AHA guidelines
Fisetin's potential CYP3A4/CYP1A2 interactions could affect statins, anticoagulants, and antiplatelet drugs — cardiac patients need cardiologist supervision.
Moderate EvidenceGrynkiewicz & Demchuk, Frontiers in Chemistry — doi:10.3389/fchem.2019.00159
Surrogate markers (arterial stiffness, FMD) do not guarantee clinical benefit — many interventions improving surrogate markers fail to reduce actual events.
Strong EvidenceClinical research methodology — Multiple reviews
Senescent endothelial cells, vascular smooth muscle cells, and macrophages accumulate in atherosclerotic plaques, contributing to vascular aging.
Moderate EvidenceVascular senescence research — Multiple reviews
Mediterranean diet (PREDIMED trial) has strong clinical evidence for cardiovascular risk reduction — far better supported than any supplement.
Strong EvidencePREDIMED trial — NEJM landmark study
Citations & External Resources
ClinicalTrials.gov — NCT06133634 Vascular Function Trial
PubMed — Fisetin research
ACC/AHA Cardiovascular Guidelines
PREDIMED Trial — NEJM
Frontiers in Chemistry — Grynkiewicz & Demchuk 2019 (Bioavailability)
EBioMedicine — Yousefzadeh et al. 2018
What If Your Afternoon Energy Crash Isn't About Sleep?
New research points to mitochondrial dysfunction as the hidden driver of chronic fatigue. Here's what you can do about it today.
Related Reading
Fisetin: The Complete Evidence-Based Guide
Fisetin & Vascular Function: Endothelial Research
Fisetin & Healthy Aging: What Research Shows
References (3)
Written by
ReCellence™ Editorial Team
Health Content Specialists
Medically reviewed by
Medical Review Board
MD, PhD
Last updated: March 8, 2026
Last medical review: March 8, 2026